Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences

Rhea-AI Summary

Keros Therapeutics (Nasdaq: KROS) announced that CEO Jasbir S. Seehra, Ph.D., will present at three healthcare conferences in late February and March 2026: Oppenheimer (Feb 25), TD Cowen (Mar 3) and Leerink Partners (Mar 10).

Each presentation format is listed (corporate presentation or fireside chat) and archived replays will be available on the company investor website for up to 90 days after each event.

News Market Reaction – KROS

+2.35%

+2.35% Session close to close

In the Feb 19 session, KROS gained 2.35%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement outlines upcoming conference appearances where Keros’s CEO will present the compan...

Analysis

This announcement outlines upcoming conference appearances where Keros’s CEO will present the company’s story and pipeline, with replays available for up to 90 days. Against a backdrop of prior capital return initiatives and strengthened cash reported in late 2025, these events give management a platform to update investors on strategic and clinical progress. Key factors to watch include any new data, partnership developments, or changes in long-term plans communicated during these presentations.

Key Figures

Oppenheimer conference time: February 25, 2026 at 11:20 a.m. ET TD Cowen conference time: March 3, 2026 at 9:50 a.m. ET Leerink conference time: March 10, 2026 at 1:00 p.m. ET +1 more

4 metrics

Oppenheimer conference time February 25, 2026 at 11:20 a.m. ET Oppenheimer 36th Annual Healthcare Life Sciences Conference presentation slot

TD Cowen conference time March 3, 2026 at 9:50 a.m. ET TD Cowen 46th Annual Health Care Conference fireside chat

Leerink conference time March 10, 2026 at 1:00 p.m. ET Leerink Partners Global Healthcare Conference fireside chat

Replay availability up to 90 days Archived replays accessible on Keros investor website after each event

Historical Context

5 past events · Latest: Nov 20 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Nov 20	Tender offer results	Positive	+3.4%	Final results of cash tender offer completing capital return program.
Nov 19	Tender offer prelim	Positive	-3.9%	Preliminary tender offer results and expected share repurchase details.
Nov 05	Q3 2025 earnings	Positive	+0.6%	Reduced net loss, strong cash, and advancing Takeda and KER-065 programs.
Oct 20	Tender offer launch	Positive	+9.8%	Commencement of cash tender offer under capital return program.
Oct 15	Capital return plan	Positive	-4.0%	Agreements to repurchase shares and outline of $375M capital return plan.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent news has focused on capital return and tender offers, with generally positive reactions but some notable divergences around tender details.

Recent Company History

Over the past few months, Keros emphasized shareholder returns via a $375 million capital return program, including issuer tender offers at $17.75 per share and related director and fund transactions. Q3 2025-11-05 results highlighted a sharply reduced net loss and substantial cash, alongside Takeda-partnered and internal pipeline plans. The current conference participation update follows this capital return and earnings phase, positioning management to communicate strategy and clinical progress to investors after major buyback activity.

Key Terms

transforming growth factor-beta, tgf-ß

2 terms

transforming growth factor-beta medical

"disorders that are linked to dysfunctional signaling of the transforming growth factor-beta"

Transforming growth factor-beta (TGF-β) is a naturally occurring signaling protein that helps control cell growth, inflammation and tissue repair, acting like a traffic cop that tells cells when to divide, change form or calm down. It matters to investors because drugs that block or boost TGF-β can treat cancers, fibrotic diseases and immune disorders, affecting clinical trial outcomes, regulatory risk and the commercial potential of biopharma assets.

tgf-ß medical

"dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins"

Transforming growth factor beta (TGF-ß) is a naturally occurring protein that helps cells talk to each other and controls processes like growth, scarring and immune response. Think of it as a traffic signal for tissues that can either slow down or redirect cell behavior. Investors watch TGF-ß because drugs that change its signals can treat cancer, fibrosis and immune diseases, so changes in research results or regulatory news can strongly affect a biotech’s value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

LEXINGTON, Mass., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that Keros’ President and Chief Executive Officer Jasbir S. Seehra, Ph.D., will present at the following healthcare conferences:

Oppenheimer 36th Annual Healthcare Life Sciences Conference

• Date and Time: Wednesday, February 25, 2026 at 11:20 a.m. Eastern time
• Link: https://event.summitcast.com/view/CTtthLh2Bi2D9aYoKpvtEv/V8otRzLTXb58JhbhcNWND2
• Format: Corporate Presentation
  
  

TD Cowen 46th Annual Health Care Conference

• Date and Time: Tuesday, March 3, 2026 at 9:50 a.m. Eastern time
• Link: https://event.summitcast.com/view/9z5g2VrV6e6rbCqQgDRoHA/gAsAzarzXsTWnurjwhWYFM
• Format: Fireside Chat Presentation
  
  

Leerink Partners Global Healthcare Conference

• Date and Time: Tuesday, March 10, 2026 at 1:00 p.m. Eastern time
• Link: https://event.summitcast.com/view/mT9poctHDNthc6b89WqVjf/4HAHET37grTuDD8oiMF2x7
• Format: Fireside Chat Presentation
  
  

For each presentation, an archived replay will be accessible in the Investors section of the Keros website at https://ir.kerostx.com for up to 90 days following the conclusion of each event.

About Keros Therapeutics, Inc.

Keros is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the TGF-ß family of proteins. Keros is a leader in understanding the role of the TGF-ß family of proteins, which are master regulators of the growth, repair and maintenance of a number of tissues, including blood, bone, skeletal muscle, adipose and heart tissue. By leveraging this understanding, Keros has discovered and is developing protein therapeutics that have the potential to provide meaningful and potentially disease-modifying benefit to patients. Keros’ lead product candidate, rinvatercept (KER-065), is being developed for the treatment of Duchenne muscular dystrophy and for the treatment of amyotrophic lateral sclerosis. Keros’ most advanced product candidate, elritercept, is being developed for the treatment of cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndrome and in patients with myelofibrosis.

Contacts

Investor Contact:
Justin Frantz
jfrantz@kerostx.com
617-221-6042

Media Contact:
Mahmoud Siddig / Adam Pollack / Viveca Tress
Joele Frank, Wilkinson Brimmer Katcher
(212) 355-4449

FAQ

When will Keros Therapeutics (KROS) present at the Oppenheimer Healthcare Life Sciences Conference?

Keros will present on Feb 25, 2026 at 11:20 a.m. ET. According to the company, the session is a corporate presentation and an archived replay will be available on the investor website for up to 90 days after the event.

What format is the KROS presentation at the TD Cowen 46th Annual Health Care Conference on March 3, 2026?

The KROS presentation on Mar 3, 2026 at 9:50 a.m. ET is a fireside chat. According to the company, investors can access an archived replay on the company's investor site for up to 90 days after the event.

Where can investors watch the archived replays of Keros Therapeutics (KROS) conference presentations?

Archived replays are available in the investor section of the Keros website for up to 90 days after each event. According to the company, each replay will be posted following the conclusion of the respective conference presentation.

Who will represent Keros Therapeutics (KROS) at the March 10, 2026 Leerink Partners Global Healthcare Conference?

CEO Jasbir S. Seehra, Ph.D., will present on Mar 10, 2026 at 1:00 p.m. ET. According to the company, the session is a fireside chat and will be archived on the investor site for 90 days post-event.

How long will Keros Therapeutics (KROS) keep conference presentation replays online after each event?

Keros will keep each archived replay available for up to 90 days following the conclusion of the event. According to the company, replays will be posted in the investor relations section of the corporate website.

How can investors access live links for Keros Therapeutics (KROS) presentations scheduled in Feb–Mar 2026?

Live links for each presentation are provided for the scheduled events and are accessible through the event platforms. According to the company, links are available as listed for each conference and replays will follow on the investor site.